Clinical Trials · NCT00590343

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Louisiana State University Health Sciences Center in New Orleans
Enrollment
23
Start date
Nov 2004
Locations
1 site, United States
Primary endpoint
Change in biochemical markers.
View Octreotide compound reference